Cancer :: Treatment induced factor causes cancer progression
In advanced cancer, anti-tumor therapies often work only partially or not at all, and tumors progress following treatment.
In advanced cancer, anti-tumor therapies often work only partially or not at all, and tumors progress following treatment.
Eating red meat increases a woman?s chance of developing breast cancer, according to new research from the University of Leeds.
A senior UK oncologist Chris Hamilton admitted that thousands of men with prostate cancer are being given unnecessary and potentially harmful drug treatment to clear hospital waiting lists in UK.
A research team at the Vanderbilt-Ingram Cancer Center, led by Carlos Arteaga, M.D., reports in the May issue of the Journal of Clinical Investigation that radiation and chemotherapy increase circulating levels of the growth factor TGF-beta, circulating cancer cells, and tumor metastases in a mouse model of metastatic breast cancer.
In a ground-breaking study published in the top journal, Cell, Dr. James Dennis, senior investigator at the Samuel Lunenfeld Research Institute at Mount Sinai Hospital, has discovered a new role for sugars on proteins.
Surviving breast cancer is both a physical and an emotional ordeal, but the consensus among researchers is that life generally returns to normal for most women within two years of completing treatment.
Scientists have uncovered the molecular pathways involved in the inhibition of protein synthesis in cells by aspirin, a discovery that may have implications for the treatment of cancer.
Flavonoids. You?ve heard of them — the good-for-your-health compounds found in plants that we enjoy in red wine, dark chocolate, green tea and citrus fruits. Mother Nature is an ace at making them, producing different ones by the thousands, but no chemist has figured out a good way to synthesize a special class of these chemicals in the laboratory. Until now.
Cancer researchers estimate that the number of cancer cases will more than double over the next 25 years, with the great majority of the increase in developing countries.
Cell Genesys, Inc. (Nasdaq: CEGE) announced final, updated results from its second multi-center Phase 2 trial of GVAX immunotherapy for prostate cancer which evaluated escalating doses of the immunotherapy in 80 patients with metastatic hormone-refractory prostate cancer (HRPC).